Patent Assignment
Reel/Frame 044938/0257
Security Interest
Recorded: 2017-12-21
Pages: 35
Assignor
AMARIN PHARMACEUTICALS IRELAND LIMITED
Executed: 2017-12-20
Assignee
CPPIB CREDIT EUROPE S.À R.L.
10-12 BOULEVARD ROOSEVELT, LUXEMBOURG, L-2450, LUXEMBOURG
Covered Properties
(218)
Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
Application:
11/361,069 →
Publication:
US US20060252833A1
Pharmaceutical Composition Comprising Omega-3 Fatty Acid and Hydroxy-Derivative of a Statin and Methods of Using Same
Application:
12/888,994 →
Publication:
US US20110071176A1
Highly Purified Ethyl Epa and Other Epa Derivatives
Application:
12/951,620 →
Publication:
US US20110065793A1
Compositions and Methods for Treating and/or Preventing Cardiovascular Disease
Application:
13/040,977 →
Publication:
US US20110218243A1
Pharmaceutical Composition Comprising Eicosapentaenoic Acid and Nicotinic Acid and Methods of Using Same
Application:
13/061,865 →
Publication:
US US20110236476A1
Pharmaceutical Compositions Comprising Epa and a Cardiovascular Agent and Methods of Using the Same
Application:
13/124,628 →
Publication:
US US20120093922A1
Methods of Treating Hypertriglyceridemia
Application:
13/198,221 →
Publication:
US US20110288171A1
Pharmaceutical Compositions Comprising Epa and a Cardiovascular Agent and Methods of Using the Same
Stable Pharmaceutical Composition and Methods of Using Same
Application:
13/266,374 →
Publication:
US US20120100208A1
Compositions and Methods for Lowering Triglycerides Without Raising Ldl-C Levels in a Subject on Concomitant Statin Therapy
Application:
13/359,114 →
Publication:
US US20130012580A1
Methods of Treating Hypertriglyceridemia
Application:
13/403,694 →
Publication:
US US20120156285A1
Methods of Treating Hypertriglyceridemia
Application:
13/404,666 →
Publication:
US US20120157530A1
Compositions and Methods for Lowering Triglycerides
Application:
13/404,686 →
Publication:
US US20120157531A1
Pharmaceutical Compositions Comprising Epa and a Cardiovascular Agent and Methods of Using the Same
Application:
13/418,591 →
Publication:
US US20120172432A1
Highly Purified Ethyl Epa and Other Epa Derivatives
Application:
13/439,392 →
Publication:
US US20120195963A1
Methods of Treating Hypertriglyceridemia
Application:
13/482,720 →
Publication:
US US20120237594A1
Methods of Treating Hypertriglyceridemia
Application:
13/671,197 →
Publication:
US US20130131170A1
Pharmaceutical Composition Comprising Eicosapentaenoic Acid and Nicotinic Acid and Methods of Using Same
Pharmaceutical Compositions Comprising Epa and a Cardiovascular Agent and Methods of Using the Same
Application:
13/758,332 →
Publication:
US US20130195972A1
Methods of Treating Hypertriglyceridemia
Application:
13/903,742 →
Publication:
US US20130331447A1
Pharmaceutical Composition Comprising an Omega-3 Fatty Acid and a Hydroxy-Derivative of a Statin and Methods of Using Same
Application:
13/908,911 →
Publication:
US US20140080850A1
Methods of Treating Hypercholesterolemia
Application:
13/909,555 →
Publication:
US US20130324607A1
Methods for Treating Hypertriglyceridemia
Application:
13/928,737 →
Publication:
US US20140005265A1
Methods for Treating Cardiovascular Disease in Statin-Tolerant Subjects
Application:
13/928,800 →
Publication:
US US20140004183A1
Methods of Treating Pediatric Metabolic Syndrome
Application:
13/928,863 →
Publication:
US US20140005264A1
Low Eructation Composition and Methods for Treating and/or Preventing Cardiovascular Disease in a Subject with Fish Allergy/Hypersensitivity
Application:
13/990,316 →
Publication:
US US20140127289A1
Compositions and Methods for Treating and/or Preventing Cardiovascular Disease
Application:
14/012,625 →
Publication:
US US20140128464A1
Highly Purified Ethyl Epa and Other Epa Derivatives
Application:
14/028,451 →
Publication:
US US20140073692A1
Methods of Increasing Epa Blood Levels
Application:
14/145,030 →
Publication:
US US20140213648A1
Methods of Treating or Preventing Nonalcoholic Steatohepatitis (Nash)and/or Primary Biliary Cirrhosis(Pbs)
Application:
14/145,106 →
Publication:
US US20140187633A1
Compositions and Methods for Treating and/or Preventing Cardiovascular Disease
Application:
14/173,076 →
Publication:
US US20140221676A1
Compositions Comprising Eicosapentaenoic Acid and 5-Htp and Methods of Use Thereof
Application:
14/173,521 →
Publication:
US US20140221452A1
Compositions Comprising Eicosapentaenoic Acid and Diazoxide and Methods of Use Thereof
Application:
14/173,545 →
Publication:
US US20140221358A1
Pharmaceutical Compositions Comprising Epa and a Cardiovascular Agent and Methods of Using the Same
Application:
14/175,515 →
Publication:
US US20140155455A1
Compositions and Methods for Lowering Triglycerides in a Subject on Concomitant Statin Therapy
Application:
14/176,631 →
Publication:
US US20140155481A1
Compositions and Methods for Reducing a Fatty Acid Desaturation Index in a Subject in Need Thereof
Application:
14/193,463 →
Publication:
US US20140249220A1
Methods of Reducing or Preventing Oxidative Modification of Membrane Polyunsaturated Fatty Acids
Application:
14/193,531 →
Publication:
US US20140249225A1
Co-Administration of Atorvastatin and Ethyl Eicosapentaenoic Acid or a Derivative Thereof
Application:
14/193,632 →
Publication:
US US20140249200A1
Co-Administration of Warfarin and Ethyl Eicosapentaenoate
Application:
14/193,915 →
Publication:
US US20140249214A1
Compositions Comprising Eicosapentaenoic Acid and Krill Oil and Methods of Use Thereof
Application:
14/210,761 →
Publication:
US US20140271907A1
Methods of Treating Traumatic Brain Injury
Application:
14/210,836 →
Publication:
US US20140275252A1
Pharmaceutical Composition Comprising Eicosapentaenoic Acid and Derivatives Thereof and a Statin
Application:
14/213,553 →
Publication:
US US20140271841A1
Methods of Reducing Apolipoprotein C-III
Methods of Treating Hypertriglyceridemia
Application:
14/296,026 →
Publication:
US US20140357717A1
Co-Administration of Rosiglitazone and Eicosapentaenoic Acid or a Derivative Thereof
Methods of Reducing Ldl-P
Application:
14/411,835 →
Publication:
US US20150157593A1
Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
Application:
14/441,111 →
Publication:
US US20150265566A1
Methods of Treating a Cardiovascular Disorder in a Subject on Apo-C3 Modulating Therapy
Application:
14/453,167 →
Publication:
US US20150045431A1
Methods of Treating a Cardiovascular Disorder and/or Joint Pain in a Subject on Glucosamine Therapy
Application:
14/457,366 →
Publication:
US US20150051282A1
Methods of Treating or Preventing Prostate Cancer
Application:
14/477,034 →
Publication:
US US20150065572A1
Co-Administration of Omeprazole and Eicosapentaenoic Acid or a Derivative Thereof
Application:
14/481,023 →
Publication:
US US20150073050A1
Pharmaceutical Compositions Comprising Omega-3 Fatty Acids
Compositions and Methods for Lowering Triglycerides in a Subject on Concomitant Statin Therapy
Application:
14/656,437 →
Publication:
US US20150190361A1
Methods of Treating Mixed Dyslipidemia
Stable Pharmaceutical Composition and Methods of Using Same
Application:
14/709,937 →
Publication:
US US20150238455A1
Methods of Treating Hypercholesterolemia
Application:
14/718,986 →
Publication:
US US20150250756A1
Methods for Treating Hypertriglyceridemia
Application:
14/721,765 →
Publication:
US US20150250757A1
Compositions and Methods for Treating and/or Preventing Cardiovascular Disease
Application:
14/723,799 →
Publication:
US US20150335607A1
Methods of Increasing Epa Blood Levels
Application:
14/724,284 →
Publication:
US US20150258051A1
Pharmaceutical Composition Comprising Omega-3 Fatty Acid and Hydroxy-Derivative of a Statin and Methods of Using Same
Methods of Reducing Rlp-C
Methods of Reducing Apolipoprotein C-Iii
Methods of Treating Hypertriglyceridemia
Compositions and Methods for Treating or Preventing Obesity in a Subject in Need Thereof
Compositions and Methods for Lowering Triglycerides
Application:
15/095,860 →
Publication:
US US20160220522A1
Compositions and Methods for Lowering Triglycerides
Application:
15/182,695 →
Publication:
US US20160287546A1
Methods of Reducing or Preventing Oxidation of Small Dense Ldl or Membrane Polyunsaturated Fatty Acids
Application:
15/258,565 →
Publication:
US US20170151202A1
Methods of Treating Mixed Dyslipidemia
Methods of Reducing or Preventing Oxidation of Small Dense Ldl or Membrane Polyunsaturated Fatty Acids
Compositions Comprising Eicosapentaenoic Acid and a Hydroxyl Compound and Methods of Use Thereof
Methods of Treating Hypertriglyceridemia
Application:
15/408,077 →
Publication:
US US20170119722A1
Compositions Comprising Eicosapentaenoic Acid and Mipomersen and Methods of Use Thereof
Compositions and Methods for Lowering Triglycerides Without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
Compositions and Methods for Treating and/or Preventing Cardiovascular Disease
Application:
15/413,093 →
Publication:
US US20170128406A1
Stable Pharmaceutical Composition and Methods of Using Same
Methods of Reducing or Preventing Oxidation of Small Dense LDL or Membrane Polyunsaturated Fatty Acids
Compositions and Methods for Reducing a Fatty Acid Desaturation Index in a Subject in Need Thereof
Application:
15/424,949 →
Publication:
US US20170143657A1
Methods of Reducing or Preventing Oxidative Modification of Membrane Polyunsaturated Fatty Acids
Application:
15/549,722 →
Publication:
US US20180028480A1
Methods of Reducing the Risk of a Cardiovascular Event in a Subject on Statin Therapy
Methods of Reducing the Risk of a Cardiovascular Event in a Subject on Statin Therapy
Application:
15/607,050 →
Publication:
US US20170258754A1
Methods of Reducing the Risk of a Cardiovascular Event in a Subject on Statin Therapy
Methods of Treating Pediatric Metabolic Syndrome
Application:
15/672,603 →
Publication:
US US20180085334A1
Methods of Treating or Preventing Prostate Cancer
Co-Administration of Atorvastatin and Ethyl Eicosapentaenoic Acid or a Derivative Thereof
Application:
15/716,764 →
Publication:
US US20180015071A1
Methods and Systems for Offering Financial Products
Methods of Reducing Triglycerides and Ldl-C
Chimeric Double-Stranded Nucleic Acid
Compositions and Methods for Lowering Levels of High-Sensitivity C-Reactive Protein (Hs-Crp) in a Subject
Pharmaceutical Composition Comprising Eicosapentaenoic Acid and Low Dose Nicotinic and Methods of Using Same
Application:
61/093,506 →
Methods of Treating and/or Preventing Cardiovascular Diseases and Disorders
Application:
61/151,291 →
Methods of Treating Hypertriglyceridemia
Application:
61/173,755 →
Pharmaceutical Compositions Comprising Epa and a Cardiovascular Agent and Methods of Using the Same
Application:
61/173,759 →
Stable Pharmaceutical Composition and Methods of Using Same
Application:
61/173,763 →
Compositions and Methods for Lowering Triglycerides Without Raising Ldl-C Levels in a Subject on Concomitant Statin Therapy
Application:
61/187,132 →
Pharmaceutical Composition Comprising Omega-3 Fatty Acid and Hydroxy-Derivative of a Statin and Methods of Using Same
Application:
61/245,086 →
Compositions and Methods for Treating and/or Preventing Cardiovascular Disease
Application:
61/310,443 →
Low Eructation Composition and Methods for Treating and/or Preventing Cardiovascular Disease in a Subject with Fish Allergy/Hypersensitivity
Application:
61/417,691 →
Methods of Treating Hypertriglyceridemia
Application:
61/556,573 →
Compositions and Methods for Lowering Levels of High-Sensitivity (Hs-Crp) in a Subject
Application:
61/584,013 →
Pharmaceutical Composition Comprising Omega-3 Fatty Acid and Hydroxy-Derivative of a Statin and Methods of Using Same
Application:
61/655,879 →
Methods of Treating Hypercholesterolemia
Application:
61/655,890 →
Compositions and Methods for Lowering Levels of High-Sensitivity C-Reactive Protein (Hs-Crp) in a Subject
Application:
61/656,347 →
Methods of Treating Cardiovscular Disease in Statin-Intolerant Subjects
Application:
61/666,428 →
Methods of Reducing Ldl-P
Application:
61/666,433 →
Methods of Treating Pediatric Metabolic Syndrome
Application:
61/666,437 →
Methods of Treating Hypertriglyceridemia
Application:
61/666,442 →
Methods of Reducing the Risk of a Cardiovascular Event in a Subject on Statin Therapy
Application:
61/666,447 →
Methods of Treating Hypertriglyceridemia
Application:
61/670,408 →
Compositions and Methods for Lowering Triglycerides Without Raising Ldl-C Levels in a Subject on Concomitant Statin Therapy
Application:
61/723,108 →
Methods of Treating or Preventing Nonalcoholic Steatohepatitis and/or Primary Biliary Cirrhosis
Application:
61/747,667 →
Compositions Comprising Epa and Obeticholic Acid and Methods of Use Thereof
Application:
61/747,678 →
Methods of Increasing Epa Blood Levels
Application:
61/747,689 →
Compositions Comprising Eicosapentaenoic Acid and Diazoxide and Methods of Use Thereof
Application:
61/761,388 →
Compositions Comprising Eicosapentaenoic Acid and 5-Htp and Methods of Use Thereof
Application:
61/761,392 →
Compositions and Methods for Treating and/or Preventing Cardiovascular Disease
Application:
61/761,398 →
Methods of Reducing Apolipoprotein C-Iii
Application:
61/761,399 →
Compositions Comprising Eicosapentaenoic Acid and Mipomersen and Methods of Use Thereof
Application:
61/764,344 →
Compositions Comprising Eicosapentaenoic Acid and a Hydroxyl Compound and Methods of Use Thereof
Application:
61/766,464 →
Methods of Reducing or Preventing Oxidative Modification of Membrane Polyunsaturated Fatty Acids
Application:
61/771,423 →
Co-Administration of Warfarin and Ethyl Eicosapentaenoate
Application:
61/771,431 →
Co-Administration of Atorvastatin and Ethyl Eicosapentaenoic Acid or a Derivative Thereof
Application:
61/771,441 →
Compositions and Methods for Reducing a Fatty Acid Desaturation Index in a Subject in Need Thereof
Application:
61/771,446 →
Compositions Comprising Eicosapentaenoic Acid and Krill Oil and Methods of Use Thereof
Application:
61/784,205 →
Methods of Treating Traumatic Brain Injury
Application:
61/784,303 →
Compositions and Methods for Treating or Preventing Obesity in a Subject in Need Thereof
Application:
61/784,404 →
Pharmaceutical Composition Comprising Eicosapentaenoic Acid and Derivatives Thereof and a Statin
Application:
61/798,126 →
Methods of Reducing Apolipoprotein C-Iii
Application:
61/809,138 →
Compositions and Methods for Reducing a Fatty Acid Desaturation Index in a Subject in Need Thereof
Application:
61/828,938 →
Co-Administration of Atorvastatin and Ethyl Eicosapentaenoic Acid or a Derivative Thereof
Application:
61/828,942 →
Co-Administration of Warfarin and Ethyl Eicosapentaenoate
Application:
61/828,948 →
Compositions and Methods for Treating and/or Preventing Cardiovascular Disease
Application:
61/830,463 →
Methods of Treating Hypertriglyceridemia
Application:
61/830,891 →
Co-Administration of Rosiglitazone and Ethyl Eicosapentaenoic Acid or a Derivative Thereof
Application:
61/832,057 →
Compositions and Methods for Lowering Triglycerides and Crp in a Subject on Concomitant Statin Therapy Having Metabolic Syndrome
Application:
61/833,253 →
Methods of Treating a Cardiovascular Disorder in a Subject on Apo-C3 Modulating Therapy
Application:
61/862,577 →
Methods of Treating a Cardiovascular Disorder and/or Joint Pain in a Subject on Glucosamine Therapy
Application:
61/865,863 →
Methods of Treating or Preventing Prostate Cancer
Application:
61/873,596 →
Co-Administration of Omeprazole and Eicosapentaenoic Acid or a Derivative Thereof
Application:
61/875,512 →
Co-Administration of Rosiglitazone and Eicosapentaenoic Acid or a Derivative Thereof
Application:
61/875,779 →
Compositions and Methods for Lowering Triglycerides Without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
Application:
61/889,315 →
Compositions and Methods for Lowering Triglycerides and Crp in a Subject on Concomitant Statin Therapy Having Metabolic Syndrome
Application:
61/898,133 →
Methods of Treating Hypertriglyceridemia
Application:
61/900,078 →
Methods of Reducing or Preventing Oxidative Modification of Membrane Polyunsaturated Fatty Acids
Application:
61/928,826 →
Methods of Reducing Rlp-C
Application:
62/010,847 →
Methods of Reducing or Preventing Oxidation of Small Dense Ldl in a Hypertriglyceridemic Subject
Application:
62/012,739 →
Methods of Reducing or Preventing Oxidation of Small Dense Ldl in a Hypertriglyceridemic Subject
Application:
62/051,032 →
Methods of Reducing Rlp-C
Application:
62/077,478 →
Methods of Reducing or Preventing Oxidation of Small Dense Ldl in a Hypertriglyceridemic Subject
Application:
62/127,117 →
Methods of Reducing or Preventing Oxidative Modification of Membrane Polyunsaturated Fatty Acids
Application:
62/127,123 →
Methods of Reducing or Preventing Oxidation of Small Dense Ldl in a Hypertriglyceridemic Subject
Application:
62/171,637 →
Methods of Reducing or Preventing Oxidation of Small Dense Ldl or Membrane Polyunsaturated Fatty Acids
Application:
62/216,013 →
Methods of Reducing or Preventing Oxidation of Small Dense LDL or Membrane Polyunsaturated Fatty Acids
Application:
62/308,525 →
Compositions and Methods for Lowering Triglycerides in a Subject With Renal Insufficiency
Application:
62/508,789 →
Methods of Treating or Preventing Bone Loss
Application:
62/545,796 →
Methods of Reducing or Preventing Oxidation of High Density Lipoprotein (HDL)
Application:
62/545,809 →
Methods of Reducing or Preventing Oxidation of High Density Lipoprotein (HDL)
Application:
62/586,268 →
Highly Purified Epa for Treatment of Schizophrenia and Related Disorders
Patent:
6,384,077 →
Application:
09/492,741 →
Therapeutic Combinations of Fatty Acids
Patent:
6,479,544 →
Application:
09/893,473 →
Highly Purified Ethyl Epa and Other Epa Derivatives for Psychiatric and Neurological Disorders
Highly Purified Ethyl Epa and Other Epa Derivatives
Methods of Treating Hypertriglyceridemia
Stable Pharmaceutical Composition and Methods of Using Same
Compositions and Methods for Lowering Triglycerides Without Raising Ldl-C Levels in a Subject on Concomitant Statin Therapy
Compositions and Methods for Lowering Triglycerides
Methods of Treating Hypertriglyceridemia
Methods of Treating Hypertriglyceridemia
Methods of Treating Hypertriglyceridemia
Methods of Treating Hypertriglyceridemia
Methods of Treating Hypertriglyceridemia
Compositions and Methods for Lowering Triglycerides in a Subject on Concomitant Statin Therapy
Methods for Lowering Triglycerides Without Raising Ldl-C Levels in a Subject on Concomitant Statin Therapy
Stable Pharmaceutical Composition and Methods of Using Same
Methods of Treating Mixed Dyslipidemia
Methods of Treating Hypertriglyceridemia
Methods of Treating Hypertriglyceridemia
Methods of Treating Hypertriglyceridemia
Methods of Treating Hypertriglyceridemia
Stable Pharmaceutical Composition and Methods of Using Same
Stable Pharmaceutical Composition and Methods of Using Same
Stable Pharmaceutical Composition and Methods of Using Same
Methods of Treating Hypertriglyceridemia
Stable Pharmaceutical Composition and Methods of Using Same
Stable Pharmaceutical Composition and Methods of Using Same
Methods of Treating Hypertriglyceridemia
Methods of Treating Hypertriglyceridemia
Compositions and Methods for Lowering Levels of High-Sensitivity C-Reactive Protein (Hs-Crp) in a Subject
Stable Pharmaceutical Composition and Methods of Using Same
Stable Pharmaceutical Composition and Methods of Using Same
Stable Pharmaceutical Composition and Methods of Using Same
Methods of Treating Hypertriglyceridemia
Methods of Treating Hypertriglyceridemia
Methods of Treating Hypertriglyceridemia
Stable Pharmaceutical Composition and Methods of Using Same
Stable Pharmaceutical Composition and Methods of Using Same
Stable Pharmaceutical Composition and Methods of Using Same
Stable Pharmaceutical Composition and Methods of Using Same
Methods of Treating Mixed Dyslipidemia
Methods of Treating Mixed Dyslipidemia
Compositions and Methods for Lowering Triglycerides Without Raising Ldl-C Levels in a Subject on Concomitant Statin Therapy
Stable Pharmaceutical Composition and Methods of Using Same
Stable Pharmaceutical Composition and Methods of Using Same
Stable Pharmaceutical Composition and Methods of Using Same
Lighting Fixture and Light-Emitting Diode Light Source Assembly
Compositions Comprising Epa and Obeticholic Acid and Methods of Use Thereof
Methods of Reducing Apolipoprotein C-Iii
Pharmaceutical Compositions Comprising Fatty Acids
Compositions Comprising Eicosapentaenoic Acid and Mipomersen and Methods of Use Thereof
Compositions Comprising Eicosapentaenoic Acid and a Hydroxyl Compound and Methods of Use Thereof
Compositions and Methods for Treating or Preventing Obesity in a Subject in Need Thereof
Stable Pharmaceutical Composition and Methods of Using Same
Methods of Reducing the Risk of a Cardiovascular Event in a Subject on Statin Therapy
Compositions and Methods for Lowering Triglycerides Without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
Stable Pharmaceutical Composition and Methods of Using Same
Methods of Reducing the Risk of a Cardiovascular Event in a Subject on Statin Therapy
Methods of Reducing the Risk of a Cardiovascular Event in a Subject on Statin Therapy
Methods of Reducing the Risk of a Cardiovascular Event in a Subject on Statin Therapy
Methods of Reducing the Risk of a Cardiovascular Event in a Subject on Statin Therapy
Methods of Reducing the Risk of a Cardiovascular Event in a Subject on Statin Therapy
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
May 25, 2012
From: PEET, MALCOLM; VADDADI, KRISHNA S.
To: LAXDALE LIMITED
Reel/Frame 028270/0071 →
Change of Name
May 25, 2012
From: LAXDALE LIMITED
To: AMARIN NEUROSCIENCE LIMITED
Reel/Frame 028275/0763 →
Proof of Ownership of Shares
May 25, 2012
From: AMARIN NEUROSCIENCE LIMITED
To: AMARIN CORPORATION PLC
Reel/Frame 028275/0333 →
Assignment of Assignor's Interest
May 30, 2012
From: PEET, MALCOLM; VADDADI, KRISHNA S.
To: LAXDALE LIMITED
Reel/Frame 028291/0162 →
Assignment of Assignor's Interest
May 30, 2012
From: MANKU, MEHAR
To: AMARIN CORPORATION PLC.
Reel/Frame 028291/0058 →
Assignment of Assignor's Interest
May 30, 2012
From: MANKU, MEHAR; OSTERLOH, IAN; WICKER, PIERRE; BRAECKMAN, RENE
To: AMARIN PHARMA, INC.
Reel/Frame 028291/0106 →
Assignment of Assignor's Interest
May 30, 2012
From: MANKU, MEHAR; OSTERLOH, IAN; WICKER, PIERRE; BRAECKMAN, RENE
To: AMARIN PHARMA, INC.
Reel/Frame 028291/0098 →
Assignment of Assignor's Interest
May 30, 2012
From: ROWE, JONATHAN
To: AMARIN PHARMA, INC.
Reel/Frame 028291/0077 →
Assignment of Assignor's Interest
May 30, 2012
From: MANKU, MEHAR; ROWE, JONATHAN
To: AMARIN CORPORATION PLC.
Reel/Frame 028291/0129 →
Change of Name
May 30, 2012
From: LAXDALE LIMITED
To: AMARIN NEUROSCIENCE LIMITED
Reel/Frame 028301/0246 →
Proof of Ownership of Shares
May 30, 2012
From: AMARIN NEUROSCIENCE LIMITED
To: AMARIN CORPORATION PLC
Reel/Frame 028301/0228 →
Assignment of Assignor's Interest
May 31, 2012
From: AMARIN CORPORATION PLC
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 028295/0289 →
Assignment of Assignor's Interest
May 31, 2012
From: AMARIN PHARMA INC.
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 028295/0491 →
Assignment of Assignor's Interest
Jun 11, 2012
From: AMARIN CORPORATION PLC
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 028351/0358 →
Security Agreement
Dec 19, 2012
From: AMARIN PHARMACEUTICALS IRELAND LIMITED
To: BIOPHARMA SECURED DEBT FUND II HOLDINGS CAYMAN LP
Reel/Frame 029499/0087 →
Assignment of Assignor's Interest
Jun 27, 2013
From: SONI, PARESH
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 030698/0919 →
Assignment of Assignor's Interest
Jun 27, 2013
From: SONI, PARESH; BRAECKMAN, RENE; STIRTAN, WILLIAM
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 030699/0263 →
Assignment of Assignor's Interest
Jul 8, 2013
From: MANKU, MEHAR; OSTERLOH, IAN; WICKER, PIERRE; BRAECKMAN, RENE
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 030749/0769 →
Assignment of Assignor's Interest
Jul 19, 2013
From: MASON, RICHARD PRESTON
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 030841/0329 →
Assignment of Assignor's Interest
Jul 19, 2013
From: MASON, RICHARD PRESTON
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 030840/0579 →
Assignment of Assignor's Interest
Aug 5, 2013
From: MANKU, MEHAR; OSTERLOH, IAN; WICKER, PIERRE; BRAECKMAN, RENE
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 030960/0014 →
Assignment of Assignor's Interest
Aug 21, 2013
From: MANKU, MEHAR; ROWE, JONATHAN
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 031056/0214 →
Assignment of Assignor's Interest
Dec 31, 2013
From: MANKU, MEHAR; OSTERLOH, IAN; WICKER, PIERR; BRAECKMAN, RENE
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 031862/0814 →
Assignment of Assignor's Interest
Jan 2, 2014
From: MANKU, MEHAR
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 031911/0297 →
Patent Security Assignment and Assumption Agreement
Dec 20, 2017
From: BIOPHARMA SECURED DEBT FUND II HOLDINGS CAYMAN LP
To: CPPIB CREDIT EUROPE S.À R.L.
Reel/Frame 044956/0395 →